← Eichor
Study identifier: NCT06937892 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Transdiagnostic Metacognitive Therapy Compared to Disorder-Specific Cognitive-Behavioral Therapy for Anxiety Disorders

Condition: Generalized Anxiety Disorder (GAD) · Social Anxiety Disorder (SAD) · Posttraumatic Stress Disorder (PTSD)  ·  Sponsor: Karolinska Institutet

PhaseNA
Planned participants86
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Background Anxiety disorders are the most prevalent psychiatric disorders around the world. Effective treatment consists of pharmacotherapy or psychological treatment based on cognitive-behavioral therapy (CBT) and these treatment options are recommended in clinical guidelines, with CBT as the first-line treatment for anxiety disorders. However, only 50% of patients with anxiety disorders achieve remission status following CBT and 20% of patients drop out of CBT. Metacognitive therapy (MCT) represents an alternative treatment approach to CBT. The theoretical model of MCT emphasizes the role of dysfunctional metacognitions (rather than cognitions, as in CBT), particularly negative metacognitions, in the development and maintenance of anxiety disorders and other psychiatric disorders. Metacognitions refer to cognitions about cognition, for example, a belief such as "When I start worrying, I cannot stop". Several meta-analyses indicate that MCT may be superior to CBT for various psychiatric disorders. However, more studies with larger samples are required to draw firm conclusions about the effectiveness of MCT. An alternative approach to disorder-specific treatment is transdiagnostic treatment; that is, the application of a single, generic protocol for several disorders. There are advantages of transdiagnostic treatments in comparison to disorder-specific treatments in terms of therapist learnability (i.e., easier to learn one protocol than several) and dissemination into ro…

This description comes directly from the study's public registry record.

Talk to the study team

Benjamin Bohman, PhD  ·  +46 70 171 34 43  ·  benjamin.bohman@ki.se

Nathalie Petersén, MSc  ·  +46 76 208 22 21  ·  nathalie.petersen@ki.se

Always discuss trial participation with your own doctor first.

Locations (1)

Stockholm North Psychiatry ClinicStockholm, SwedenRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06937892